Thursday, 24 Jul 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    Pacific Petroleum Completes Acquisition of U.S. Oil & Gas Assets from a portfolio company of a prominent private equity group
    Pacific Petroleum Completes Acquisition of U.S. Oil & Gas Assets from a portfolio company of a prominent private equity group
    24/07/2025
    Desay Battery Unveils Proactive-Safety-Focused Energy Storage Technologies
    Desay Battery Unveils Proactive-Safety-Focused Energy Storage Technologies
    24/07/2025
    SEMI Reports Global Total Semiconductor Equipment Sales Forecast to Reach 5.5 Billion in 2025
    SEMI Reports Global Total Semiconductor Equipment Sales Forecast to Reach $125.5 Billion in 2025
    22/07/2025
    The Third China International Supply Chain Expo Concludes in Beijing
    The Third China International Supply Chain Expo Concludes in Beijing
    22/07/2025
    AV-Comparatives Publishes World’s Largest Independent Enterprise Cybersecurity Solution Test
    AV-Comparatives Publishes World’s Largest Independent Enterprise Cybersecurity Solution Test
    22/07/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • june
  • news
  • global
  • july
  • Business
  • announced
  • today
  • Tech
  • company
  • will
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Business

New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options

Business Wire
Last updated: 04/06/2025 11:54 PM
Business Wire
Share
4 Min Read
New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options
SHARE
New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options
  • The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer drug in patients with breast and lung cancer and active brain metastases, and leptomeningeal disease from solid tumors.
  • These results were presented as an oral presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, with select results simultaneously published in Nature Medicine.
  • MEDSIR’s DEMETHER clinical trial was mentioned during abstract discussion due to the relevance of its strategy.

CHICAGO–(BUSINESS WIRE)–Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II study funded by Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, evaluates the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases and leptomeningeal disease, serious complications associated with advanced stages of the cancer.

- Advertisement -




- Advertisement -

The study was carried out to evaluate HER3-DXd in patients with metastatic breast cancer (mBC) and advanced non-small cell lung cancer (aNSCLC) with active brain metastases, and patients with leptomeningeal disease from solid tumors. This is an antibody-drug conjugate to target HER3, a protein receptor found on the surface of cancer cells in brain metastases. HER3-DXd is an investigational agent consisting of a fully human anti-HER3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADC Technology payload causes tumor DNA damage, killing cancer cells within and surrounding the tumor microenvironment

The study showed promising results, which were presented today in an oral session. Results from the leptomeningeal cohort have been simultaneously published in the renowned journal Nature Medicine due to its potential benefit in patients with a high unmet medical need. In patients with breast cancer and brain metastases, intracranial responses were observed across all breast cancer subtypes, including luminal, HER2-positive, and triple-negative.

- Advertisement -

A NEW HOPE FOR DIFFICULT-TO-TREAT METASTASES

- Advertisement -

“This study represents a significant advancement in our understanding of how to treat brain metastases and leptomeningeal disease, and we are hopeful that our findings will pave the way for new, effective therapies for these patients,” stated Dr. Matthias Preusser, MD, Medical Oncologist and Head of the Clinical Division of Oncology, Medical University of Vienna and Principal Investigator of TUXEDO-3. Dr. Rupert Bartsch, MD, PhD, Consultant Hematology and Medical Oncology, Medical University of Vienna, added: “Brain metastases and leptomeningeal disease represent severe complications in cancer, leading to increased morbidity and mortality, and HER3-DXd could be a promising therapeutic alternative for these patients.”

Read more about TUXEDO-3 here: https://www.medsir.org/clinical-trials/tuxedo-3

- Advertisement -

SHOWCASING PROMISING COLLABORATIVE TRIALS AT ASCO

- Advertisement -

MEDSIR’s trial DEMETHER, an international, phase II trial exploring the maintenance of trastuzumab and pertuzumab following trastuzumab deruxtecan as induction treatment for HER2-positive recurrent metastatic breast cancer patients, was mentioned during today’s Discussion of LBA1008. DEMETHER’s strategy is to optimize the sequence to increase patients’ progression free survival (PFS) while improving their quality of life.

The relevance of this mention highlighted the ability of MEDSIR for anticipating patients’ needs and designing strategical trials to keep on pushing the barriers of clinical research. MEDSIR active presence at the ASCO Annual Meeting 2025 reinforces its leadership in excellence-driven oncology research and highlights its focus on addressing unmet needs in cancer treatment, with the aim of not leaving any patient left behind.

- Advertisement -

ABOUT MEDSIR For further information: www.medsir.org

- Advertisement -

Contacts

Media
Sergio Aguilar sergio.aguilar@medsir.org
Eduardo MartĂ­n Espallargas eduardo.martin@medsir.org

- Advertisement -
ZEISS CLARUS 700 Receives NMPA Approval in China
Alkegen Enters Full Production of EV Battery Fire Protection Aerogels
Vish Iyer Joins Caelux as Managing Director, India and Middle East, to Spearhead Strategic Growth and Market Expansion in Two of the World’s Fastest-Growing Solar Markets
JAMining Expands FCA-Regulated Cloud Mining Services Amid Surging Crypto Market Activity
RadioMedix Debuts Proprietary bench top Pb Generator to Support Targeted Alpha Therapy Development
TAGGED:activeadvancedamericanannouncedbrainbreastcancercellschicagobusinessclinicalcompanydiseasedxdherdxdinternationalleptomeningealmedicalmedsirmetastasespatientspositiveResearchresultssocietystudytodaytrialtumortuxedowireleading
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

iMerit Unveils Scholars – A Handpicked Global Network of Cognitive Experts for Advanced GenAI Training
Business

iMerit Unveils Scholars – A Handpicked Global Network of Cognitive Experts for Advanced GenAI Training

10/07/2025

2025 GENESIS SCOTTISH OPEN TEES UP ICONIC PLAYERS AND EXHILARATING FAN EXPERIENCES

11/07/2025
KBRA Assigns AA Rating, Stable Outlook to the City of Jacksonville, FL Special Revenue Bonds, Series 2025
Business

KBRA Assigns AA Rating, Stable Outlook to the City of Jacksonville, FL Special Revenue Bonds, Series 2025

19/07/2025
Dentsply Sirona Prices Offering of 0 million of Junior Subordinated Notes
Health

Dentsply Sirona Prices Offering of $550 million of Junior Subordinated Notes

06/06/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?